drugset
drugset / Trial / NCT07478952

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age

NCT07478952 ↗

Phase 1 Recruiting 120 enrolled ModernaTX, Inc.
RandomizedParallel-groupOpen-labelPrevention

Summary

The main objective of this trial is to evaluate the safety and immunogenicity of mRNA-1189 after intradermal and intramuscular delivery.

Timeline

Start
2026-03-17
Primary completion
2027-05-15
Completion
2027-05-15

Drugs

EvaluationDrugModalityDoseRoute
Subject mRNA-1189 Vaccine — Intrathecal

Indications

Epstein-Barr virus infection